Depression Drugs Industry to Garner US$ 24.3 Billion and Growing at a CAGR of 2.3% by 2030

𝐃𝐞𝐩𝐫𝐞𝐬𝐬𝐢𝐨𝐧 𝐃𝐫𝐮𝐠𝐬 𝐌𝐚𝐫𝐤𝐞𝐭: 𝐈𝐧𝐭𝐫𝐨𝐝𝐮𝐜𝐭𝐢𝐨𝐧

According to the report, the global depression drugs market was valued at US$ 18.9 Bn in 2019 and is expected to attain a market value of US$ 24.3 Bn at a CAGR of 2.3% from 2020 to 2030. Major depressive disorder (MDD), schizophrenia and bipolar I disorder, Obsessive-Compulsive Disorders (OCD), and anxiety disorder are some of the different types of depression. Various drug classes are used to treat depression. These include Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs), atypical antidepressants, and tricyclic antidepressants. Rise in prevalence of depression and increase in incidence of depression among the geriatric population is boosting the global depression drugs.

North America dominated the global depression drugs market in 2019. This trend is anticipated to continue during the forecast period. Growth in awareness about the availability of new drugs to treat depression and presence of major companies in the region are expected to drive the depression drugs market in North America. Asia Pacific is likely to be a highly lucrative region of the global depression drugs market during the forecast period.

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐚 𝐬𝐚𝐦𝐩𝐥𝐞 𝐨𝐟 𝐭𝐡𝐢𝐬 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐫𝐞𝐩𝐨𝐫𝐭 𝐚𝐭 (𝐔𝐬𝐞 𝐂𝐨𝐫𝐩𝐨𝐫𝐚𝐭𝐞 𝐌𝐚𝐢𝐥 𝐈𝐝 𝐟𝐨𝐫 𝐐𝐮𝐢𝐜𝐤 𝐑𝐞𝐬𝐩𝐨𝐧𝐬𝐞) - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1151

𝐑𝐢𝐬𝐞 𝐢𝐧 𝐏𝐫𝐞𝐯𝐚𝐥𝐞𝐧𝐜𝐞 𝐨𝐟 𝐃𝐞𝐩𝐫𝐞𝐬𝐬𝐢𝐨𝐧 𝐚𝐧𝐝 𝐈𝐧𝐜𝐫𝐞𝐚𝐬𝐞 𝐢𝐧 𝐆𝐞𝐫𝐢𝐚𝐭𝐫𝐢𝐜 𝐏𝐨𝐩𝐮𝐥𝐚𝐭𝐢𝐨𝐧 𝐭𝐨 𝐃𝐫𝐢𝐯𝐞 𝐌𝐚𝐫𝐤𝐞𝐭

MDD is a commonly diagnosed form of depression. In 2015, around 16.1 million adults aged 18 years and above in the U.S. experienced at least one major depression episode. This represented 6.7% of all adults in the country. Depression is the leading cause of disability among people aged between 15 and 44 in the U.S. More than 41,000 suicides are committed every year in the U.S. Depression is one of the most common illnesses among the elderly population. In addition to the common risk factors prevalent among all age groups, chronic diseases, restricted mobility, bereavement, abuse, isolation, and loss of income are the major risk factors for depression among the geriatric population. The prevalence of depression among adults aged 65 and older is estimated to be between 5% and 10%. Depression is projected to be the second leading cause of disease burden in this age group by 2020.

𝐀𝐭𝐲𝐩𝐢𝐜𝐚𝐥 𝐀𝐧𝐭𝐢𝐝𝐞𝐩𝐫𝐞𝐬𝐬𝐚𝐧𝐭𝐬 𝐃𝐫𝐮𝐠 𝐂𝐥𝐚𝐬𝐬 𝐭𝐨 𝐃𝐨𝐦𝐢𝐧𝐚𝐭𝐞 𝐌𝐚𝐫𝐤𝐞𝐭

Based on drug class, the global depression drugs market has been divided into Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs), atypical antidepressants, tricyclic antidepressants, and others. The atypical antidepressants segment dominated the global depression drugs market in 2019. This trend is projected to continue during the forecast period, as it is first-line of treatment, and due to increase in cases of depression and launch of new drugs.

𝐒𝐜𝐡𝐢𝐳𝐨𝐩𝐡𝐫𝐞𝐧𝐢𝐚 𝐚𝐧𝐝 𝐁𝐢𝐩𝐨𝐥𝐚𝐫 𝐈 𝐃𝐢𝐬𝐨𝐫𝐝𝐞𝐫 𝐭𝐨 𝐛𝐞 𝐏𝐫𝐨𝐦𝐢𝐬𝐢𝐧𝐠 𝐃𝐢𝐬𝐞𝐚𝐬𝐞 𝐓𝐲𝐩𝐞

In terms of disease type, the global depression drugs market has been classified into Major Depressive Disorder (MDD), schizophrenia and bipolar I disorder, Obsessive-Compulsive Disorders (OCD), anxiety disorder, and others. The schizophrenia and bipolar I disorder segment is expected to expand at the highest CAGR during the forecast period. Rise in cases of schizophrenia and bipolar I disorder and increase in research on the treatment of this disorder are driving the segment. The World Health Organization considers bipolar disorder to be the sixth-largest cause of disability across the globe. According to the WHO data published in October 2019, 20 million people across the globe have been affected with schizophrenia.

𝐁𝐮𝐲 𝐭𝐡𝐢𝐬 𝐏𝐫𝐞𝐦𝐢𝐮𝐦 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭 | 𝐈𝐦𝐦𝐞𝐝𝐢𝐚𝐭𝐞 𝐃𝐞𝐥𝐢𝐯𝐞𝐫𝐲 𝐀𝐯𝐚𝐢𝐥𝐚𝐛𝐥𝐞 𝐚𝐭 - https://www.transparencymarketresearch.com/checkout.php?rep_id=1151<ype=S

𝐑𝐞𝐭𝐚𝐢𝐥 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐢𝐞𝐬 𝐒𝐞𝐠𝐦𝐞𝐧𝐭 𝐀𝐜𝐜𝐨𝐮𝐧𝐭𝐞𝐝 𝐟𝐨𝐫 𝐌𝐚𝐣𝐨𝐫 𝐒𝐡𝐚𝐫𝐞 𝐨𝐟 𝐆𝐥𝐨𝐛𝐚𝐥 𝐌𝐚𝐫𝐤𝐞𝐭

Based on distribution channel, the global depression drugs market has been categorized into retail pharmacies, hospital pharmacies, and online pharmacies. The retail pharmacies segment led the global depression drugs market in terms of revenue in 2019. This trend is anticipated to continue during the forecast period. Increase in number of depression drugs being dispensed through retail pharmacies and rise in number of retail pharmacies in developing countries make these a major channel of distribution.

𝐍𝐨𝐫𝐭𝐡 𝐀𝐦𝐞𝐫𝐢𝐜𝐚 𝐭𝐨 𝐋𝐞𝐚𝐝 𝐆𝐥𝐨𝐛𝐚𝐥 𝐌𝐚𝐫𝐤𝐞𝐭

The global depression drugs market has been split into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global depression drugs market in 2019. It was followed by Europe. The introduction of new drugs to treat depression and high prevalence of mental illness in developed countries such as the U.S. drive the depression drugs market in North America. The depression drugs market in Asia Pacific is anticipated to expand at a higher CAGR compared to that in other regions from 2020 to 2030. Growth of the depression drugs market in Asia Pacific can be ascribed to rise in prevalence of depression disorders and increase in awareness about the treatment of depression in the region.

𝐂𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐢𝐨𝐧 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞

The global depression drugs market is fragmented in terms of number of players. Key players operating in the global depression drugs market include Johnson & Johnson, Otsuka Pharmaceutical Co., Ltd, Allergan, Novartis AG, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Abbott, Pfizer, and GlaxoSmithKline. New product development through robust R&D activities and mergers & acquisitions are the key strategies adopted by these players in the global depression drugs market.

𝐃𝐞𝐩𝐫𝐞𝐬𝐬𝐢𝐨𝐧 𝐃𝐫𝐮𝐠𝐬 𝐌𝐚𝐫𝐤𝐞𝐭: 𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧

𝐃𝐞𝐩𝐫𝐞𝐬𝐬𝐢𝐨𝐧 𝐃𝐫𝐮𝐠𝐬 𝐌𝐚𝐫𝐤𝐞𝐭, 𝐛𝐲 𝐃𝐫𝐮𝐠 𝐂𝐥𝐚𝐬𝐬
Selective Serotonin Reuptake Inhibitors (SSRIs)
Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
Atypical Antidepressants
Tricyclic Antidepressants
Others (CNS stimulants, monoamine oxidase inhibitors, etc.)

𝐃𝐞𝐩𝐫𝐞𝐬𝐬𝐢𝐨𝐧 𝐃𝐫𝐮𝐠𝐬 𝐌𝐚𝐫𝐤𝐞𝐭, 𝐛𝐲 𝐃𝐢𝐬𝐞𝐚𝐬𝐞 𝐓𝐲𝐩𝐞
Major Depressive Disorder
Schizophrenia and Bipolar I Disorder
Obsessive-Compulsive Disorders (OCD)
Anxiety Disorder
Others (ADHD, SSRI-induced disorder, etc.)

𝐃𝐞𝐩𝐫𝐞𝐬𝐬𝐢𝐨𝐧 𝐃𝐫𝐮𝐠𝐬 𝐌𝐚𝐫𝐤𝐞𝐭, 𝐛𝐲 𝐃𝐢𝐬𝐭𝐫𝐢𝐛𝐮𝐭𝐢𝐨𝐧 𝐂𝐡𝐚𝐧𝐧𝐞𝐥
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies

𝐌𝐨𝐫𝐞 𝐓𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐑𝐞𝐩𝐨𝐫𝐭𝐬 𝐛𝐲 𝐓𝐫𝐚𝐧𝐬𝐩𝐚𝐫𝐞𝐧𝐜𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 -

𝐌𝐞𝐝𝐢𝐜𝐚𝐥 𝐈𝐦𝐚𝐠𝐢𝐧𝐠 𝐄𝐪𝐮𝐢𝐩𝐦𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭 - https://www.prnewswire.com/news-releases/medical-imaging-equipment-market-to-expand-at-cagr-of-5-4-during-forecast-period-observes-tmr-study-301524565.html

𝐌𝐞𝐝𝐢𝐜𝐚𝐥 𝐋𝐚𝐬𝐞𝐫 𝐒𝐲𝐬𝐭𝐞𝐦𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 - https://www.globenewswire.com/news-release/2022/03/29/2411924/0/en/Medical-Laser-Systems-Market-to-Develop-at-CAGR-of-12-During-Forecast-Period-Notes-TMR-Study.html

𝐀𝐛𝐨𝐮𝐭 𝐔𝐬 𝐓𝐫𝐚𝐧𝐬𝐩𝐚𝐫𝐞𝐧𝐜𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.

Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.

𝐂𝐨𝐧𝐭𝐚𝐜𝐭 𝐔𝐬

Nikhil Sawlani
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453

This release was published on openPR.